drug
ACTEMRA
updated 5mo agoby Genentech Inc
community read0 votes
🐶 often sniffed alongside
top 8- tagApproval264 co-mentions · 72 sources
- drugtocilizumab253 co-mentions · 73 sources
- drugTYENNE16 co-mentions · 8 sources
- drugRNS-608 co-mentions · 8 sources
- companyFresenius Kabi USA LLC8 co-mentions · 8 sources
- drugAVTOZMA8 co-mentions · 4 sources
- companyCelltrion Inc4 co-mentions · 4 sources
- companyChugai Pharmaceutical Co Ltd1 co-mentions · 1 sources
all catalysts(0)
nothing on the calendar yet
Trials studying ACTEMRA
- phase2Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma
- phase3Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
- phase3A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
- phase2A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- phase1To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
- phase1A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
- phase3A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
- phase2A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
News(2)
- Fresenius Kabi Issues Nationwide Recall of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL Vials Due to Presence of Glass ParticlesFOR IMMEDIATE RELEASE – August 10, 2026 – LAKE ZURICH, Ill.— Fresenius Kabi, an operating company of the Fresenius Group, is recalling one lot of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL (…fda_medwatch · 1mo ago
- Dr Silbermann on Clinical Trial Design Considerations in Multiple MyelomaRebecca Silbermann, MD, MMS, outlines key trial design considerations in multiple myeloma, including supportive care measures and end point selection.onclive · 4mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that